1. Short follow-up duration (6 months). 2. No measurement of inflammatory biomarkers (e.g., hs-CRP). 3. No assessment of infection risk. 4. Underpowered for individual endpoint analysis (e.g., death, stroke). 5. Single-center study, potentially limiting generalizability. The gene discussed is CRP; the disease is infection.